Denali Therapeutics Inc (STU:4DN)
€ 21.91 +1 (+4.78%) Market Cap: 3.55 Bil Enterprise Value: 2.96 Bil PE Ratio: 0 PB Ratio: 4.91 GF Score: 39/100

Denali Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 12, 2026 / 10:00PM GMT
Release Date Price: €16.49 (-1.11%)
Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst

My pleasure to have our next presenting company, Denali Therapeutics. Sitting up here on stage with me is Alex Schuth, who is, of course, Chief Operating Officer as well as CFO, double duty. Alex, thank you for making the hopefully short trip over to see us in the desert today.

Alexander Schuth
Denali Therapeutics Inc - Chief Financial Officer, Chief Operating Officer, Company Secretary

All right. Well, again, thank you, Tazeen, for inviting us for a fantastic conference. But really also thank you for following us for many years now and for your --

Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst

Not that old.

Alexander Schuth
Denali Therapeutics Inc - Chief Financial Officer, Chief Operating Officer, Company Secretary

And the always very thoughtful commentary on us. So much appreciated. So great to be here today. It's a special time for us at Denali. As we just had our first drug approved in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot